Literature DB >> 8609343

Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD).

G Torre-Amione1, S Kapadia, C Benedict, H Oral, J B Young, D L Mann.   

Abstract

OBJECTIVES: This study sought to assess proinflammatory cytokine levels in patients in the studies of left ventricular dysfunction trial (SOLVD) in relation to both their New York Heart Association functional classification and their neurohormonal status before randomization.
BACKGROUND: Elevated levels of tumor necrosis factor-alpha have been identified in 30% to 40% of patients with heart failure. However, it is unclear which subsets of patients with heart failure elaborate tumor necrosis factor-alpha. It is also unclear what the mechanism for the increased expression of proinflammatory cytokines is.
METHODS: Tumor necrosis factor-alpha and interleukin-6 levels were analyzed by enzymes-linked immunoassay using randomly selected plasma samples from patients in functional classes I to III who were enrolled in neurohormonal substudies of the SOLVD trial; age-matched healthy subjects served as the control group.
RESULTS: Plasma levels of tumor necrosis factor-alpha (p < 0.001) were elevated in patients in functional classes I to III ([mean +/- SD] 1.95 +/- 0.54, 2.63 +/- 0.48, 6.4 +/- 1.9 pg/ml, respectively) compared with age-matched control subjects (0.75 +/- 0.05 pg/ml) and were progressively elevated in relation to decreasing functional status of the patient. Plasma levels of interleukin-6 (p < 0.001) were elevated in patients in functional classes I to III (3.3 +/- 0.55, 6.2 +/- 1.1, 5.22 +/- 0.9 pg/ml, respectively) compared with age-matched control subjects (1.8 +/- 0.5 pg/ml and were progressively elevated in relation to decreasing functional status of the patient. Cox proportional-hazards analysis showed that there was a trend toward significance between plasma tumor necrosis factor-alpha (p < 0.07) and survival, whereas there was no significant relation for plasma interleukin-6 (p < 0.72). Except for atrial natriuretic factor, which correlated weakly (r = 0.23, p = 0.04) with circulating tumor necrosis factor-alpha levels, there was no significance correlation between neurohormonal and proinflammatory cytokine levels.
CONCLUSIONS: Circulating levels of proinflammatory cytokines increase in patients as their functional heart failure classification deteriorates. Moreover, activation of the neurohumoral axis is unlikely to completely explain the elaboration of proinflammatory cytokines in heart failure.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8609343     DOI: 10.1016/0735-1097(95)00589-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  276 in total

1.  The pharmacokinetics of etanercept in patients with heart failure.

Authors:  O Soran; A M Feldman; V M Schneider; R Hanna; D L Mann; J M Korth-Bradley
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

Review 2.  The role of anti-cytokine therapy in the failing heart.

Authors:  A Deswal; A Misra; B Bozkurt
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

Review 3.  Cytokines and their receptors in cardiovascular diseases--role of gp130 signalling pathway in cardiac myocyte growth and maintenance.

Authors:  K Yamauchi-Takihara; T Kishimoto
Journal:  Int J Exp Pathol       Date:  2000-02       Impact factor: 1.925

Review 4.  Pathophysiology of heart failure: a look at the future.

Authors:  R M Delgado; J T Willerson
Journal:  Tex Heart Inst J       Date:  1999

Review 5.  Activation of cytokines as a mechanism of disease progression in heart failure.

Authors:  B Bozkurt
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 6.  Peripheral limitations of maximal aerobic capacity in patients with chronic heart failure.

Authors:  Stuart D Katz; Haoyi Zheng
Journal:  J Nucl Cardiol       Date:  2002 Mar-Apr       Impact factor: 5.952

7.  Tumour necrosis factor alpha concentration and collateral flow in patients with coronary artery disease and normal systolic left ventricular function.

Authors:  C Seiler; T Pohl; M Billinger; B Meier
Journal:  Heart       Date:  2003-01       Impact factor: 5.994

Review 8.  Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation.

Authors:  Weiwei Li; Brian Olshansky
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

9.  Pediatric and adult dilated cardiomyopathy represent distinct pathological entities.

Authors:  Meghna D Patel; Jayaram Mohan; Caralin Schneider; Geetika Bajpai; Enkhsaikhan Purevjav; Charles E Canter; Jeffrey Towbin; Andrea Bredemeyer; Kory J Lavine
Journal:  JCI Insight       Date:  2017-07-20

10.  Soluble tumor necrosis factor receptors and heart failure risk in older adults: Health, Aging, and Body Composition (Health ABC) Study.

Authors:  Catherine N Marti; Hassan Khan; Douglas L Mann; Vasiliki V Georgiopoulou; Kirsten Bibbins-Domingo; Tamara Harris; Annemarie Koster; Anne Newman; Stephen B Kritchevsky; Andreas P Kalogeropoulos; Javed Butler
Journal:  Circ Heart Fail       Date:  2013-12-09       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.